Dr. Greg Marchand Named to the Fulbright Specialist Roster by the U.S. Department of State
FOR IMMEDIATE RELEASE
MESA, Ariz. — March 15, 2022
Since 2019, The Marchand Institute has displayed a paragraph on all publications proudly stating their dedication to diversity, inclusion, and the maintenance of a workplace free of racism and sexism. This declaration, in accordance with our not-for-profit mission for women’s health, is very much a part of what we are as a leading research institute. We strongly value the diverse backgrounds of our brilliant research staff, and seek to continue to add diverse individuals to our team. As of today, as a leader in surgical research, we now recommend that all research institutions follow our lead and include a statement on diversity and inclusion in all of their publications. From our perspective this is equally as important as the required statements disclosing conflicts of interest and sources of funding. An example of this statement can be found in our published works in many top level prestigious journals (JAMA, Gray Journal, etc. etc.), and an example is below:
“Statement on Commitment to Diversity and Inclusion: The Marchand Institute remains committed to diversity and tolerance in its research, and actively maintains a workplace free of racism and sexism. Greater than half of the authors for this study are female, and many represent diverse backgrounds and under-represented ethnic groups.”
About Dr. Greg Marchand
Greg J. Marchand, MD, FACS, FACOG, FICS, is a dual board-certified obstetrician-gynecologist and minimally invasive gynecologic surgeon practising in Mesa, Arizona. He holds the ABOG Focused Practice Designation in Minimally Invasive Gynecologic Surgery and directs the Marchand Institute for Minimally Invasive Surgery, a 501(c)(3) tax-exempt non-profit research and educational corporation (EIN 42-2857240). He is Program Director of an SLS-accredited fellowship in Minimally Invasive and Robotic Gynecologic Surgery, holds three issued United States patents, and has served as Principal Investigator on eight FDA clinical trials. His systematic reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised with the Cochrane Risk of Bias 2 tool. He accepts no industry funding for his research.
Media Contact
Maria A. Sainz
Director of Communications and Media Relations
maria@marchandobgyn.com
(480) 999-0905
Newsroom and press kit · Full publication list · Research methodology · Expert commentary topics
###
Related posts
